Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance

Trends in Cancer

Volumn 1, Issue 1, 2015, Pages 66-75

  Medler, Terry R ^a   Cotechini, Tiziana ^a   Coussens, Lisa M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; HUMAN; IMMUNOREGULATION; NEOPLASM; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY;

EID: 84957836940     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2015.07.008     Document Type: Review

References (110)

1. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
2. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 2012 309 322
3. L.M. Coussens, and et al. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339 2013 286 291
4. B. Ruffell, and L.M. Coussens Macrophages and therapeutic resistance in cancer Cancer Cell 27 2015 462 472
5. F. Klemm, and J.A. Joyce Microenvironmental regulation of therapeutic response in cancer Trends Cell Biol. 25 2015 198 213
6. M.M. Davis, and P.J. Bjorkman T-cell antigen receptor genes and T-cell recognition Nature 334 1988 395 402
7. G.L. Beatty, and et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
8. V. Zoete, and et al. Structure-based, rational design of T cell receptors Front. Immunol. 4 2013 268
9. C. Linnemann, and et al. TCR repertoires of intratumoral T-cell subsets Immunol. Rev. 257 2014 72 82
10. + tumor-reactive repertoire infiltrating human tumors J. Clin. Invest. 124 2014 2246 2259
11. M.M. Gubin, and et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Nature 515 2014 577 581
12. + T cells in a patient with epithelial cancer Science 344 2014 641 645
13. + T cells in human melanoma Nat. Med. 21 2015 81 85
14. M. Saraiva, and A. O'Garra The regulation of IL-10 production by immune cells Nat. Rev. Immunol. 10 2010 170 181
15. M.R. Crittenden, and et al. Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice Radiat. Res. 182 2014 182 190
16. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 2012 252 264
17. P. Leone, and et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells J. Natl. Cancer Inst. 105 2013 1172 1187
18. W. Zou Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat. Rev. Cancer 5 2005 263 274
19. F.S. Hodi, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
20. J.N. Graff, and et al. Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer Cancer Immunol. Res. 2 2014 399 403
21. C. Robert, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N. Engl. J. Med. 364 2011 2517 2526
22. S.L. Topalian, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454
23. J.R. Brahmer, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
24. E.B. Garon, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N. Engl. J. Med. 372 2015 2018 2028
25. M.A. Postow, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N. Engl. J. Med. 372 2015 2006 2017
26. C. Robert, and et al. Pembrolizumab versus Ipilimumab in advanced melanoma N. Engl. J. Med. 372 2015 2521 2532
27. D. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat. Rev. Immunol. 9 2009 162 174
28. C.D. Mills, and et al. M-1/M-2 macrophages and the Th1/Th2 paradigm J. Immunol. 164 2000 6166 6173
29. + T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells Cancer Cell 26 2014 623 637
30. D.G. DeNardo, and et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy Cancer Discov. 1 2011 54 67
31. E.Y. Lin, and J.W. Pollard Tumor-associated macrophages press the angiogenic switch in breast cancer Cancer Res. 67 2007 5064 5066
32. E.Y. Lin, and et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer Cancer Res. 66 2006 11238 11246
33. M. Obeid, and et al. Calreticulin exposure dictates the immunogenicity of cancer cell death Nat. Med. 13 2007 54 61
34. S.M. Pyonteck, and et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression Nat. Med. 19 2013 1264 1272
35. T. Shree, and et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer Genes Dev. 25 2011 2465 2479
36. V. Gocheva, and et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion Genes Dev. 24 2010 241 255
37. A. Mantovani, and P. Allavena The interaction of anticancer therapies with tumor-associated macrophages J. Exp. Med. 212 2015 435 445
38. + T cells and macrophages limit efficacy of radiotherapy Cancer Immunol. Res. 3 2015 518 525
39. J. Xu, and et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer Cancer Res. 73 2013 2782 2794
40. D.C. Strachan, and et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells Oncoimmunology 2 2013 e26968
41. J.B. Mitchem, and et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses Cancer Res. 73 2013 1128 1141
42. J. Escamilla, and et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy Cancer Res. 75 2015 950 962
43. + cells Am. J. Respir. Cell Mol. Biol. 44 2011 230 237
44. S.J. Priceman, and et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy Blood 115 2010 1461 1471
45. E.P. Chen, and et al. Myeloid cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function Carcinogenesis 35 2014 1788 1797
46. S. Mok, and et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy Cancer Res. 74 2014 153 161
47. Y. Zhu, and et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models Cancer Res. 74 2014 5057 5069
48. V. Malhotra, and M.C. Perry Classical chemotherapy: mechanisms, toxicities and the therapeutic window Cancer Biol. Ther. 2 Suppl. 1 2003 S2 S4
49. G. Kroemer, and et al. Immunogenic cell death in cancer therapy Annu. Rev. Immunol. 31 2013 51 72
50. L. Zitvogel, and et al. Immune parameters affecting the efficacy of chemotherapeutic regimens Nat. Rev. Clin. Oncol. 8 2011 151 160
51. L. Zitvogel, and et al. Immunological aspects of cancer chemotherapy Nat. Rev. Immunol. 8 2008 59 73
52. E. Proietti, and et al. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice J. Clin. Invest. 101 1998 429 441
53. + T cell-mediated immunity J. Exp. Med. 168 1988 2193 2206
54. + T cells: changing strategies for cancer treatment Blood 114 2009 589 595
55. A.A. Lugade, and et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity J. Immunol. 180 2008 3132 3139
56. B.C. Burnette, and et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity Cancer Res. 71 2011 2488 2496
57. O. Kepp, and et al. Immunogenic cell death modalities and their impact on cancer treatment Apoptosis 14 2009 364 375
58. E.W. Newcomb, and et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas Clin. Cancer Res. 12 2006 4730 4737
59. E.A. Reits, and et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J. Exp. Med. 203 2006 1259 1271
60. L. Zitvogel, and et al. Decoding cell death signals in inflammation and immunity Cell 140 2010 798 804
61. E.B. Golden, and et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death Oncoimmunology 3 2014 e28518
62. S. Matsumura, and et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells J. Immunol. 181 2008 3099 3107
63. D. Hallahan, and et al. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium Cancer Res. 56 1996 5150 5155
64. R.E. Vatner, and et al. Combinations of immunotherapy and radiation in cancer therapy Front. Oncol. 4 2014 325
65. S. Demaria, and et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated Int. J. Radiat. Oncol. Biol. Phys. 58 2004 862 870
66. M. Kioi, and et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice J. Clin. Invest. 120 2010 694 705
67. S.V. Kozin, and et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation Cancer Res. 70 2010 5679 5685
68. G.O. Ahn, and et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment Proc. Natl. Acad. Sci. U.S.A. 107 2010 8363 8368
69. C.L. Chang, and et al. Dose-dense chemotherapy improves mechanisms of antitumor immune response Cancer Res. 73 2013 119 127
70. S.R. Mattarollo, and et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors Cancer Res. 71 2011 4809 4820
71. L. Apetoh, and et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy Immunol. Rev. 220 2007 47 59
72. A. Tesniere, and et al. Immunogenic death of colon cancer cells treated with oxaliplatin Oncogene 29 2010 482 491
73. S. Buttiglieri, and et al. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells Int. J. Cancer 106 2003 516 520
74. A. Galetto, and et al. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells Anticancer Drugs 14 2003 833 843
75. N. Casares, and et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J. Exp. Med. 202 2005 1691 1701
76. B.G. Brenner, and R.G. Margolese The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer Cancer 68 1991 482 488
77. H.F. Sewell, and et al. Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer Int. J. Cancer 55 1993 735 738
78. + regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol. Immunother. 56 2007 641 648
79. P. Liu, and et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice J. Immunother. 33 2010 53 59
80. J.C. Doloff, and D.J. Waxman VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression Cancer Res. 72 2012 1103 1115
81. H. Khallouf, and et al. 5-Fluorouracil and interferon-alpha immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I J. Immunother. 35 2012 245 253
82. M. Chittezhath, and et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression Immunity 41 2014 815 829
83. A. Sica, and et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy Eur. J. Cancer 42 2006 717 727
84. J.W. Pollard Trophic macrophages in development and disease Nat. Rev. Immunol. 9 2009 259 270
85. K. Bryniarski, and et al. Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice Pharmacol. Rep. 61 2009 550 557
86. M. Ryder, and et al. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression PLoS ONE 8 2013 e54302
87. N.I. Affara, and et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas Cancer Cell 25 2014 809 821
88. A.J. van den Eertwegh, and et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol. 13 2012 509 517
89. F.S. Hodi, and et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS Nat. Clin. Pract. Oncol. 5 2008 557 561
90. J.C. Yang, and et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J. Immunother. 30 2007 825 830
91. B.C. Carthon, and et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin. Cancer Res. 16 2010 2861 2871
92. O.S. Qureshi, and et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 Science 332 2011 600 603
93. + T cells Eur. J. Immunol. 28 1998 3137 3143
94. R.S. Herbst, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
95. S.L. Topalian, and et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr. Opin. Immunol. 24 2012 207 212
96. M.E. Keir, and et al. PD-1 and its ligands in tolerance and immunity Annu. Rev. Immunol. 26 2008 677 704
97. T. Honda, and et al. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues Immunity 40 2014 235 247
98. S.L. Topalian, and et al. Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
99. E. Cha, and et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients Sci. Transl. Med. 6 2014 238ra70
100. + T cell response Sci. Transl. Med. 6 2014 254ra128
101. S.M. Ansell, and et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N. Engl. J. Med. 372 2015 311 319
102. O. Hamid, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
103. T. Powles, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
104. P. Sharma, and J.P. Allison Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential Cell 161 2015 205 214
105. J.D. Wolchok, and et al. Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2013 122 133
106. C. Twyman-Saint Victor, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 2015 373 377
107. D. Hannani, and et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy Cancer J. 17 2011 351 358
108. H.E. Teulings, and et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis J. Clin. Oncol. 33 2015 773 781
109. J.D. Wolchok, and et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin. Cancer Res. 15 2009 7412 7420
110. J. Gao, and et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience Oncogene 2015 10.1038/onc.2015.5 Published online February 9, 2015